Thermo Fisher Scientific INC.: management transactions · United States · SEC (Form 4)

About Thermo Fisher Scientific INC.

Thermo Fisher Scientific Inc. (ticker: TMO) is a global leader in scientific instrumentation, laboratory consumables, diagnostics, bioproduction, and outsourced pharma services. The company is listed in the United States on the NYSE/NASDAQ market and is headquartered in Waltham, Massachusetts. In practice, Thermo Fisher is one of the most comprehensive “picks-and-shovels” providers in life sciences and industrial science: it supplies tools and services that help customers discover drugs, test materials, run laboratories, and manufacture advanced therapies. Its positioning is often described as serving science at scale, with a portfolio spanning research, clinical, and applied markets. ([corporate.thermofisher.com](https://corporate.thermofisher.com/us/en/index/about.html?utm_source=openai)) The company traces its roots to Thermo Electron, founded in 1956, and has expanded over decades through acquisitions and portfolio building, including Fisher Scientific, to become a highly integrated global platform. Thermo Fisher reports its business through major segments such as Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. This structure gives it exposure across the full scientific workflow: molecular biology and sequencing, mass spectrometry, chromatography, sample preparation, lab equipment, specialty diagnostics, routine lab supplies, contract development and manufacturing, and clinical research services. ([sec.gov](https://www.sec.gov/Archives/edgar/data/97745/000009774525000101/tmo-20250628.htm?utm_source=openai)) From a competitive perspective, Thermo Fisher benefits from scale, brand strength, deep customer relationships, and a very broad installed base. Its flagship brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. That portfolio helps the company compete across academic research, biopharma, clinical diagnostics, and industrial testing, while also providing cross-selling opportunities and recurring consumables revenue. Geographically, Thermo Fisher has a truly global footprint, serving customers across North America, Europe, and Asia-Pacific through a wide manufacturing, commercial, and service network. ([ir.thermofisher.com](https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Expands-Global-Biobank-Leadership-Through-Strategic-Collaboration-with-PRECISE-SG100K-Singapore-to-Advance-Population-Scale-Proteomics/default.aspx?utm_source=openai)) Recent developments point to an actively managed portfolio and continued innovation. In the first quarter of 2026, Thermo Fisher reported revenue of $11.01 billion, up 6%, and highlighted several product launches in instruments, applied analysis, and cell therapy manufacturing. In January 2026, the company announced a strategic collaboration with NVIDIA to advance AI-enabled laboratory automation and improve workflow performance. In April 2026, it also announced a collaboration with PRECISE-SG100K in Singapore to support population-scale biobanking and proteomics. Separately, Thermo Fisher signed an agreement in April 2026 to sell its microbiology business to Astorg, underscoring management’s willingness to reshape the portfolio and redeploy capital. ([ir.thermofisher.com](https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Reports-First-Quarter-2026-Results/default.aspx?utm_source=openai))